04159nas a2200457   4500008004100000022001400041245007500055210006900130260000800199300001200207490000700219520297300226653001003199653001703209653001003226653001503236653004403251653002303295653001103318653001803329653001703347653001503364653001503379653001103394653002103405653003203426100001703458700001703475700001203492700001603504700001503520700001603535700001203551700001503563700001603578700001603594700001403610700001803624700001603642856004303658       1997                        eng d  a0006-497100aAllogeneic blood stem cell transplantation: considerations for donors.0 aAllogeneic blood stem cell transplantation considerations for do  cAug  a903 - 80 v903 aAllogeneic transplantation of cytokine-mobilized peripheral blood stem cells (PBSCs) is now being increasingly performed, but safety considerations for hematologically normal PBSC donors have not been fully addressed. Progenitors are generally mobilized for collection from normal donors using recombinant human granulocyte colony-stimulating factor (rhG-CSF). Although the short-term safety profile of rhG-CSF seems acceptable, experience remains limited and its optimal dose and schedule have not been defined. Minimal data exist regarding long-term safety of rhG-CSF, primarily derived from experience in patients with chronic neutropenia or cancer. An "ad hoc" workshop was recently convened among a group of investigators actively involved in the field of allogeneic stem cell transplantation to discuss the safety issues pertaining to normal PBSC donors. There was agreement on the following points: (1) On the basis of available data, it appears that rhG-CSF treatment and PBSC collection have an acceptable short-term safety profile in normal donors. However, the need for continued safety monitoring was recognized. (2) rhG-CSF doses up to 10 microg/kg/d show a consistent dose-response relationship with the mobilization (and collection) of CD34+ progenitor cells, and this dose is acceptable for routine clinical use. Whether higher doses are superior (or cost effective) remains to be determined, and they may produce more severe side effects. The potential risks of marked leukocytosis (arbitrarily defined as a leukocyte count of more than 70 x 10(9)/L) have been a concern, and rhG-CSF dose reduction is performed by many centers to maintain leukocyte counts below this level. (3) Transient post donation cytopenias, involving granulocytes, lymphocytes, and platelets, may occur and are at least partly related to the leukapheresis procedure. These are generally asymptomatic and self-limited; follow-up blood counts are not necessarily required. Reinfusion of autologous platelet-rich plasma should be considered for donors with expected postdonation thrombocytopenia (platelet count < 80 to 100 x 10(9)/L). (4) Donors should meet the eligibility criteria which apply to donors of apheresis platelets, with the exception that pediatric donors may also be considered. Any deviation from these criteria should have supporting documentation. There is insufficient information at this time to clearly establish definite contraindications for PBSC collection in a hematologically normal donor. Potential contraindications include the presence of inflammatory, autoimmune, or rheumatologic disorders, as well as atherosclerotic or cerebrovascular disease. (5) The creation of an International PBSC Donor Registry is desirable to facilitate monitoring the long-term effects of the procedure. Individual institutions or donor centers are encouraged to establish their own PBSC donor follow-up system, preferably with a standardized approach to data collection.10aAdult10aBlood Donors10aChild10aFilgrastim10aHematopoietic Stem Cell Transplantation10aHistocompatibility10aHumans10aLeukapheresis10aLeukocytosis10aLeukopenia10aRegistries10aSafety10aThrombocytopenia10aTransplantation, Homologous1 aAnderlini, P1 aKörbling, M1 aDale, D1 aGratwohl, A1 aSchmitz, N1 aStroncek, D1 aHowe, C1 aLeitman, S1 aHorowitz, M1 aGluckman, E1 aRowley, S1 aPrzepiorka, D1 aChamplin, R  uhttps://notifylibrary.org/reference/67